...
Content approved by: Dr Farzana Khan, MD, MRCGP, DFFP — Specialist in vaginal health with 20+ years’ medical experience across dermatology and gynaecology. Care is balanced, evidence-aware, and patient-centred.

Dr Farzana Khan qualified as an MD from the University of Copenhagen in 2003. She has worked in dermatology and obstetrics & gynaecology across the North of England and completed her MRCGP (CCT, 2013) and the Diploma of the Faculty of Sexual & Reproductive Health (2013).
Her clinical focus is vaginal health—including dryness/GSM, sexual function concerns, lichen sclerosus, and comfort or volume changes. She explains conservative and medical options first, then discusses regenerative or aesthetic procedures where appropriate.
Dr Farzana is a key opinion leader on women’s intimate health and been featured in the press including the daily mail and on BBC radio. Dr Farzana also trains clinicians as a Trainer with Neauvia, NuV Laser, Asclepion Juliet Laser, and RegenLab. Ongoing CPD includes IMCAS, CCR, ACE and expert training in intimate fillers, PRP and polynucleotides.
Authored and medically reviewed by Dr Farzana Khan. Last updated: 1 November 2025.

Vaginal Dryness & Genitourinary Syndrome of Menopause (GSM): A UK Guide

Last updated: 05 November 2025 • Educational only. Results vary. Not a cure.

Author: Dr Farzana Khan, MRCGP, DFFP — Women's Health GP, The Women's Health Clinic

Key Takeaways

  • GSM is the modern term for vulvovaginal and urinary changes after oestrogen falls; vaginal dryness is a hallmark symptom. [1,2,3]
  • Start simple: non-hormonal moisturisers (regularly) + lubricants (when needed) for milder symptoms. [1,3,9]
  • Most effective for persistent dryness: low-dose local (vaginal) oestrogen (cream, tablet, pessary, ring). [1,2,3,6,10]
  • Safety: low-dose local oestrogens generally don't require a progestogen; unexpected bleeding needs review. [1,5,6]
  • Recurrent UTIs post-menopause: UK guidance says consider vaginal oestrogen to reduce recurrence. [4]
  • Laser/RF for GSM: investigational in the UK (NICE IPG); the US FDA has issued safety warnings. [7,8]

Quick Start: Where Are You Right Now?

Occasional dryness during sex

Start here: Water-based lubricant + consider moisturiser 2–3× weekly

Immediate comfort from lubricant; moisturiser builds over 2–4 weeks. [1,9]

Daily soreness/itching, avoiding intimacy

Start here: Book a consultation to discuss local oestrogen; keep using moisturiser

Meaningful improvement typically by 4–8 weeks. [1,6,9]

Tried moisturisers ≥3 months, little relief

Start here: Discuss local oestrogen or non-oestrogen prescriptions

Local oestrogen shines for persistent symptoms. [1,2,3,6,10]

Recurrent UTIs (≥3/year)

Start here: Ask about vaginal oestrogen for UTI prevention

UK guidance supports this approach. [4]

Introduction

Vaginal dryness is incredibly common after menopause—and very treatable. You don't have to "put up with it." This guide explains what's happening, what actually works, and how to choose next steps that fit your life, with every claim grounded in UK-relevant evidence. [1,2,3,6,10]

What is GSM—and how does vaginal dryness fit in?

GSM = the umbrella for post-menopausal vaginal/vulval and urinary symptoms linked to low oestrogen; dryness is one of the most common. [1,2,3] The term replaces "atrophic vaginitis" to reflect that urinary symptoms often co-exist and there isn't always inflammation. [1,2,3] Recognising GSM steers a stepwise, preference-sensitive plan rather than a one-size-fits-all approach. [1,3,6]

Context (no duplication): Overview—https://thewomenshealth.clinic/vaginal-atrophy/

 

Symptoms of GSM

Genital & Vaginal Symptoms

Vaginal drynessBurning, soreness, or itchingVaginal discharge, The vagina feeling shorter or tighter

Sexual Symptoms

Pain, discomfort, or dryness during sex (dyspareunia), Light bleeding after sexLoss of libido (often due to fear of pain)

Urinary Symptoms

Needing to wee more often (frequency), Sudden desperate need to wee (urgency), Pain on urination (dysuria), Recurrent Urinary Tract Infections (UTIs)Stress incontinence
   

What changes happen after menopause?

Falling oestrogen thins and dries the vaginal lining, reduces elasticity and raises vaginal pH; the lower urinary tract is also oestrogen-sensitive, which explains urgency and recurrent infections alongside dryness. [1,2,3,6] These changes increase micro-trauma and discomfort with sex; local oestrogen directly addresses tissue health, while moisturisers/lubricants support comfort. [1,3,6,9]

See lived-experience + tips: https://thewomenshealth.clinic/vaginal-dryness/

Will vaginal dryness go away on its own?

Typically, no—GSM reflects persistently low oestrogen after menopause, so symptoms often continue or gradually worsen without treatment. [1,2,3] Severity varies; many manage well with moisturisers, while others need prescriptions. Starting early usually makes maintenance easier. [1,3,6]

Stepwise UK pathway: where should I start?

UK guidance supports a laddered approach: moisturiser/lubricant → local oestrogen for persistent/moderate–severe symptoms → prasterone/ospemifene if needed → review. [1,3,6,10]

Step 1: Moisturiser ± lubricant

What it's for: Mild dryness, friction

Escalate when: Still symptomatic after 4–6 weeks

Step 2: Local oestrogen

What it's for: Dryness, dyspareunia, vaginal health

Escalate when: Sub-optimal response or preference for alternatives

Step 3: Prasterone / Ospemifene

What it's for: Hormone-free or SERM options

Escalate when: Persistent symptoms despite trials

Step 4: Specialist review

What it's for: Complex/refractory cases, red flags

Escalate when: Diagnostic uncertainty or inadequate improvement

Shared decision-making + a maintenance plan beat one-off "courses." [1,3,6,10]

How do I know if moisturisers aren't enough?

If you've used a quality moisturiser consistently for 4–6 weeks and still have significant discomfort—or recurrent UTIs—it's time to discuss local oestrogen. [1,3,4,9] If dryness is affecting intimacy or daily life despite lubricant, step up. [1,3]

Local (vaginal) oestrogen: what to expect week by week

Weeks 1–2 (loading): frequent use; tissues begin adjusting; mild messiness/irritation is possible. [1,6,9]

Weeks 3–4: less rawness, more comfort emerging. [1,6]

Weeks 6–8: meaningful improvement for most; move to maintenance 2–3× weekly. [1,6,9]

3–6 months: benefits plateau; ongoing use keeps gains because oestrogen remains low after menopause. [1,2,3,6]

Formulations

Cream (flexible, can use externally; a bit messy). [6,9]

Tablet/Pessary (clean, simple; internal only). [6,9]

Ring (set-and-forget ~3 months; fixed dose). [6,9]

Choice is about preference, dexterity and external symptoms—not "better/worse." [1,6,9]

 

Types of Local Oestrogen Available in the UK

Your GP or menopause specialist can prescribe local oestrogen in several forms. The most common UK-prescribed options include: 

 

Vaginal Pessaries (Tablets): These are small tablets inserted with an applicator. UK brands include Vagifem® and Vagirux®. The brand Gina® is now also available over-the-counter in the UK after a pharmacist consultation. 

 

Vaginal Creams: These are applied inside and around the vagina. The most common UK brand is Ovestin®. 

 

Vaginal Rings: This is a soft, flexible ring that sits in the vagina and releases a steady dose of oestrogen. The UK brand is Estring®.

 

Safety: do I need a progestogen with local oestrogen?

No. With low-dose local oestrogens, systemic absorption is minimal, so routine progestogen isn't required; do seek assessment for any unexpected bleeding. [1,5,6] Systematic reviews/observational data do not show increased endometrial cancer risk at low vaginal doses. [5,6] This differs from systemic HRT, where endometrial protection is considered for those with a uterus. [1]

Is vaginal dryness linked to recurrent UTIs?

Yes. NICE NG112 advises considering vaginal oestrogen to reduce recurrent UTIs in post-menopausal people. [4] Oestrogen supports the vaginal epithelium and micro-environment, likely lowering susceptibility to ascending infections; clinicians combine this with hydration and other prevention strategies as appropriate. [3,4]

More on UTIs: https://thewomenshealth.clinic/urinary-tract-infections-uti/

Can vaginal DHEA help if I can't or don't want to use oestrogen?

Prasterone (DHEA) pessaries can improve dyspareunia/dryness related to GSM and are oestrogen-free (converted locally within tissues). [10,11] Suitability and access vary; it's an option when oestrogen is not preferred or tolerated. [10,11] Ospemifene (oral SERM) is another route for moderate–severe dyspareunia; risks/benefits depend on history. [10,12]

Treatment sequencing (internal): https://thewomenshealth.clinic/faq/in-what-order-should-i-try-moisturisers-local-oestrogen-devices-or-injectables/

Are hyaluronic-acid moisturisers different to lubricants?

Yes. Moisturisers support the lining between sex; lubricants reduce friction during sex/exams. [1,9] HA-based moisturisers hold water well and are generally well tolerated. [1,9] For persistent GSM, local oestrogen addresses the underlying tissue changes; moisturiser + lubricant still play supportive roles. [1,6,10]

Non-Hormonal Options: Moisturisers & Lubricants

It's important to know the difference between these two products, as they have very different jobs. Vaginal Moisturisers (for Regular Health): These are for regular use (e.g., every 2-3 days), regardless of sexual activity. They are absorbed into the vaginal tissue to improve hydration and restore moisture. Think of them as a long-acting "face moisturiser" for your vagina. Hyaluronic acid (HA) based moisturisers are excellent at holding water and are generally very well tolerated.

Vaginal Lubricants (for Sexual Activity): These are for use during sex (or pelvic exams) only. They are not absorbed; they stay on the surface to reduce friction and make sex more comfortable and less painful.

Compare products (internal):

Breastfeeding & dryness—what are safe options?

Breastfeeding can lower oestrogen and trigger GSM-like dryness; start with non-hormonal moisturisers/lubricants and discuss prescriptions individually. [1,9] Low-dose local oestrogen has minimal systemic absorption but requires a tailored conversation during lactation. [1,9]

Internal: Safe options while breastfeeding—https://thewomenshealth.clinic/faq/safe-options-for-dryness-while-breastfeeding/

Do copper or hormonal IUDs affect dryness or comfort?

IUDs don't treat GSM and generally don't cause GSM, which is driven by low oestrogen; some people have IUD-related discomfort that can be confused with dryness. [1] Review helps separate device issues (e.g., strings/position) from GSM so each can be addressed properly. [1]

Internal: IUDs and comfort—https://thewomenshealth.clinic/faq/can-copper-or-hormonal-iuds-affect-dryness-or-comfort/

Red-flag symptoms that need urgent review

Seek prompt assessment for post-menopausal bleeding, severe pain, foul discharge with fever, flank pain with fever, new lumps/ulcers, or urinary retention—these aren't typical of straightforward GSM and need timely evaluation. [1,4]

Full checklist (internal): https://thewomenshealth.clinic/faq/what-red-flag-symptoms-mean-i-should-seek-urgent-review/

Do probiotics help GSM or recurrent infections?

Evidence isn't strong enough to recommend probiotics as core therapy for GSM or for preventing post-menopausal rUTIs; consider them adjunctively if desired, but prioritise proven options like vaginal oestrogen. [3,4]

Internal: Probiotics & GSM/UTIs—https://thewomenshealth.clinic/faq/do-probiotics-help-with-gsm-or-recurrent-infections/

Can I use laser/RF if I'm on HRT?

NICE classifies vaginal laser for GSM as investigational (research-only), and the FDA warns against energy-based devices for "vaginal rejuvenation" due to unproven benefit and possible harms; this stance doesn't change if you're on HRT. [7,8] Consider evidence-based alternatives first. [1,3,6,10]

Internal: NICE & energy-based treatments—https://thewomenshealth.clinic/faq/what-does-nice-say-about-energy-based-treatments-for-dryness/

Explainer: https://thewomenshealth.clinic/vaginal-rejuvenation/

Does pelvic floor overactivity contribute to discomfort?

Yes—pelvic floor overactivity can amplify pain with sex; addressing GSM and muscle overactivity (physio, paced exposure, dilators) often works best. [1,3] Relaxation-focused pelvic physio (not "just Kegels") plus generous lubricant can break the pain–tension cycle. [1,3]

Internal: Pelvic physio & discomfort—https://thewomenshealth.clinic/faq/can-pelvic-floor-physio-help-dryness-related-discomfort/

Lichen sclerosus: follow-up, emollients & sex comfort

LS is a chronic vulval skin condition that can coexist with GSM; management uses potent topical steroids, emollients and regular follow-up; any new lesions/change warrants review. [1] If GSM is also present, local oestrogen can be added. [1]

Internal: LS service page—https://thewomenshealth.clinic/lichen-sclerosus/ | Biopsy considerations—https://thewomenshealth.clinic/faq/when-is-a-biopsy-considered-for-vulval-symptoms/

Vaginismus vs dyspareunia: how do I tell the difference?

Dyspareunia = pain with sex (many causes, including GSM); vaginismus = involuntary pelvic floor tightening that blocks/limits penetration—often co-exists with GSM in midlife. [1,3] Supportive history, optional exam, pelvic physio and psychosexual approaches help alongside GSM care. [1,3]

Internal: Dyspareunia—https://thewomenshealth.clinic/dyspareunia/ | Dilators/physio—https://thewomenshealth.clinic/faq/do-dilators-or-pelvic-floor-therapy-help-painful-sex/

Devices & aesthetics: research-only, safety first

For GSM, energy devices remain research-only in the UK; for aesthetics (fillers/PRP/skin boosters, pigmentation), evidence is limited—discuss reversibility, PIH risk and realistic expectations; prioritise safety and consent. [7,8]

Internal: Sessions/spacing—https://thewomenshealth.clinic/faq/how-many-sessions-are-typical-and-how-far-apart/ | Combining treatments—https://thewomenshealth.clinic/faq/can-i-combine-laser-rf-with-prp-or-polynucleotides-for-dryness/

When will I feel better, and how do I maintain results?

Moisturisers

2–4 weeks for comfort gains; continue as part of routine. [1,9]

Local oestrogen

Improvements over 4–8 weeks, maintained long-term 2–3× weekly. [1,6,9]

Prasterone/Ospemifene

Similar timelines; review for fit and interactions. [10,11,12]

Pelvic physio/dilators

Variable—often weeks to months with consistent practice. [1,3]

GSM is a long-term change, so think sustainable maintenance, not a one-off fix. [1,2,3,6]

Real Questions from Our Clinic

"Am I too young for this?"

Perimenopause, surgical menopause and some treatments can cause GSM-type symptoms—treat what you feel, not your age. [1,2,3]

"Do I still need local oestrogen if I'm on HRT?"

Often yes—systemic HRT may not fully resolve local vaginal changes. [1,6]

"Two weeks of cream and no change—give up?"

Too soon; tissue remodelling typically needs 6–8 weeks. [1,6,9]

"Is coconut oil fine?"

Can be irritating and not condom-safe; purpose-made vaginal products are preferable. [9]

Talking points for your appointment

Bring: your top symptoms, what you've already tried, your preferences (hormonal or not), and questions on timelines, safety and follow-up. [1,3,6,10] Ask about formulation choices (cream/tablet/pessary/ring), how to maintain benefits, and what the next step would be if needed. [1,6,9,10]

Prep tool: https://thewomenshealth.clinic/online-womens-health-interactive-triage-tool/

Book: https://thewomenshealth.clinic/online-booking/

Statistics

Local vaginal oestrogen improves dryness, dyspareunia and vaginal health indices in GSM [1,2,3,6,9,10]
Low-dose local oestrogen has not shown increased endometrial cancer risk [5,6]
Vaginal oestrogen is recommended by NICE to reduce recurrent UTIs post-menopause [4]
⚠️
Energy devices (laser/RF) are investigational for GSM in the UK; FDA cautions apply [7,8]

Conclusion & Booking

You deserve comfortable, confident, pain-free intimacy and everyday comfort—without tip-toeing around dryness. Start simple, step up when needed, and keep what works. Local oestrogen is the workhorse for persistent symptoms; non-oestrogen options exist when that's your preference; pelvic physio and thoughtful product use round out the plan. [1,3,6,9,10]

Ready to Get Help?

If you're ready to chat through options, we're here—UK-wide video and in-clinic.

References

(Accessed 05 Nov 2025)

1. NICE. Menopause: diagnosis and management (NG23). 2024 update. Available from: https://www.nice.org.uk/guidance/ng23

2. The North American Menopause Society (NAMS). The 2020 genitourinary syndrome of menopause position statement. 2020. PDF via ISSWSH: https://www.isswsh.org/images/content/2020-NAMS-GSM-Paper.pdf

3. Agency for Healthcare Research and Quality (AHRQ). Genitourinary Syndrome of Menopause: A Systematic Review (Comparative Effectiveness Review 272). 2024. Available from: https://effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-272-genitourinary-syndrome.pdf

4. NICE. Urinary tract infection (recurrent): antimicrobial prescribing (NG112). 2024 update. Available from: https://www.nice.org.uk/guidance/ng112

5. Constantine GD, Kessler G, Graham S, Goldstein SR. Endometrial safety of low-dose vaginal estrogens in menopausal women: a systematic evidence review. Menopause. 2019. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC6636806/

6. Lethaby A, et al. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2016;CD001500. Available from: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001500.pub3/full

7. NICE. IPG697: Laser therapy for symptoms of vaginal atrophy. 2018. Available from: https://www.nice.org.uk/guidance/ipg697

8. US Food & Drug Administration (FDA). FDA warns against use of energy-based devices to perform "vaginal rejuvenation". 2018. Available from: https://www.fda.gov/medical-devices/safety-communications/fda-warns-against-use-energy-based-devices-perform-vaginal-rejuvenation-or-vaginal-cosmetic

9. NHS. About vaginal oestrogen. Available from: https://www.nhs.uk/medicines/hormone-replacement-therapy-hrt/vaginal-oestrogen/about-vaginal-oestrogen/

10. Qaseem A, et al. Hormonal Treatments and Vaginal Moisturizers for GSM: Clinical Guideline. Ann Intern Med. 2024. PubMed: https://pubmed.ncbi.nlm.nih.gov/39250810/

11. Electronic Medicines Compendium (eMC). Intrarosa 6.5 mg pessary (prasterone) — SmPC. Available from: https://www.medicines.org.uk/emc/product/9986/smpc

12. British National Formulary (BNF). Ospemifene. Available from: https://bnf.nice.org.uk/drugs/ospemifene/